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Abstract
Alzheimer’s disease, type II diabetes, and other amyloid diseases are known to be
associated with the formation of amyloid aggregates. It has been thoroughly researched
whether amyloid fibrils or oligomers are the main culprit for these diseases, and recent
evidence has connected oligomers as the most disease relevant aggregate species. However,
many difficulties have arose in confirming this hypothesis. Techniques for oligomer detection
are often limited in their sensitivity, and in many cases are unable to distinguish oligomers from
rigid fibrils. Additionally, the role oligomer splay in fibril assembly is still unclear, and has led to
the belief that different types of oligomers may exist with potentially differing biological
relevance.
The first part of my research aimed to develop an assay for effectively screening
fluorescent dyes for selectivity toward a specific amyloid aggregate species. Lysozyme was
shown to undergo amyloid formation along two pathways, with a clear difference in their
kinetics. Fibril growth had a clear lag period followed by sigmodial growth, while early oligomer
growth instead transitioned the kinetics to biphasic. This transition was utilized to screen
various dyes for oligomer sensitivity, and found a promising candidate for an oligomer selective
dye in crystal violet. Additionally, concurrent kinetics of both Thioflavin-T and crystal violet
allowed me to separate the biphasic kinetics into its oligomer and fibril components.
The second part of my researched shows the formation of two distinct types of
oligomers formed by Lysozyme. These two types of oligomers formed at different time points
vii

during amyloid fibril growth and showed a clear difference in their level of cytotoxicity. This
difference highlights a main issue in determining the disease relevance of oligomers, as specific
environmental conditions can lead to the formation of oligomers with differing levels of
biological activity. Both oligomer types were characterized through a variety of techniques and
were shown to share many similarities but were found to differ in secondary structure, and in
their response to the oligomer selective antibody A11.
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Chapter 1 - Introduction

Amyloid diseases come about from the propensity of certain proteins to assemble into
long fibrils with a characteristic cross- structure called amyloid fibrils (1-4). The most infamous
amyloid diseases are Alzheimer’s and Parkinson’s Disease, but amyloid diseases are not limited
to only being neurodegenerative in nature. They can be localized around other organs in the
body or can even affect groups of organs, such as AL and Lysozyme amyloidosis. (3) These
diseases represent a growing healthcare concern, with Alzheimer’s predicted to affect more
than 150 million people by 2050. As of now essentially no amyloid diseases have a cure and in
many cases only limited treatment methods.
Amyloid fibrils were first described by Virchow in 1854 using iodine staining. Followed
by identification of their prominent birefringence in optical microscopy (6, 7). Their underlying
characteristic cross-β sheet structure was obtained 40 years later using X-ray diffraction (8).
Understanding the mechanisms of formation and the pathogenic action of amyloid aggregates
is critical in order to suppress or cure amyloid diseases eventually. This objective, however,
faces multiple obstacles. Many different proteins and peptides have the propensity to form
amyloids, such as amyloid-beta 1-42, β2 microglobulin, and hen egg white lysozyme, with no
discernable structural or functional similarities between them to explain it. There is even
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growing evidence that all peptide chains may have some propensity to form amyloid fibrils,
with some amyloids having functions beneficial to the human body (3-5]. In addition, amyloid
aggregates have been shown to assemble along multiple pathways resulting in aggregate
populations with distinct morphologies, tectorial properties, stabilities, structures and toxicities
(11-17). Namely, besides their characteristic late stage rigid fibril structures amyloid proteins
will form early stage globular oligomers and intermediates. There has been progress made in
the understanding of the growth kinetics for rigid fibrils. In particular, the role of secondary
nucleation mechanisms dominating the early stages of fibril formation is now widely accepted
(5). Much less is known about the origin of globular oligomers, which are metastable precursors
of fibrils and have been implicated as perhaps the most toxic and disease-relevant amyloid
aggregate species (1-5). Unraveling the role oligomer intermediates play in both fibril assembly
and pathophysiology, would likely provide valuable insight into the origins of, and potential
cures for amyloid diseases. However, generating and characterizing pure oligomer samples, in
particular, is challenging since they are inherently metastable, their size distributions can vary
widely, they can polymerize into so-called curvilinear fibrils, and there are indications that their
underlying structures are sensitive to the specific growth conditions chosen to generate them.
The first part of my thesis work is focused on work towards identifying novel fluorescent
indicator dyes for in situ detection of oligomers vs. fibrils. Towards that end I will exploit a
reliable method developed in our lab for growing amyloid aggregates along two distinct
assembly pathways. The first is the commonly observed sigmoidal fibril growth pathway with its
distinct lag period, absent of any discernible aggregate growth, followed by rapid nucleation
and growth of rigid fibrils. The second pathway is characterized by lag-free biphasic kinetics in
2

which global oligomers form immediately, followed by a second upswing upon fibril nucleation
and growth. Using this convenient difference in aggregation kinetics, I suggest an assay to
screen small fluorophores for potential selectivity towards either oligomers or fibrils. Some
dyes, namely Thioflavin-T have already proven to be excellent indicators of fibril growth. This
assay will allow us to identify candidates for dyes that can selectively monitor oligomer
formation in vitro and in vivo.
In the second part of my thesis work I will study the formation and origin of oligomers.
Oligomers are commonly believed to be metastable precursors of rigid fibrils that assembly
from the monomers of a given amyloid protein. However, my lab has some recent findings that
suggest that an additional species of oligomers may emerge during late stage fibril formation. If
this conclusion is true, it could be an important step forward in understanding why fibrils have
sometimes been found to be toxic to cells, despite the growing evidence that oligomers are the
most problematic species in amyloid diseases. In this thesis I describe several experiments
providing evidence that these fibril-associated aggregates are indeed oligomers, as well as
some preliminary findings that fibril-associated oligomers can form from other amyloid
proteins.
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Chapter 2 - Screening Assay for Oligomer Selective Dyes

2.1 Background
Amyloid diseases are generally identified by deposits of insoluble plaques of amyloid
fibrils in tissue (11, 12). These deposits have been shown to be birefringence, indicating they
must have an organized structure. In addition, these plaques display Congo Red and Thioflavin T
fluorescence (52). Initially the presence of these plaques in post-mortem histology were
considered diagnostic of the underlying illness, and were widely believed to be the main
underlining cause of amyloid diseases, as well.
2.1.1 From Amyloid Cascade Hypothesis to Toxic Oligomer Hypothesis
The amyloid cascade hypothesis was established as a possible explanation for the origin
of the disease (53). It was believed that a variety of factors, such as genetic mutations and
environmental effects, would increase ones propensity to have the toxic form of the amyloid
beta peptide. Amyloid beta, in turn, would form amyloid plaques, which leads to tea tangles
and neuronal loss, and results in the dementia associated with Alzheimer’s (53). This cascade
hypothesis had a number of issues, mainly that the correlation of concentration of amyloid
plaques in post-mortem brain pathology to severity of the disease is poor. Specifically,
significant plaque loads can be found in persons without disease symptoms and vice versa (62)
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Over the years the amyloid cascade hypothesis has been modified to the toxic oligomer
hypothesis. This modification was due to at least three observations. First, as mentioned
above, plaque densities did not correlate well with disease symptoms. Second, the presence of
small and long-lived oligomeric precursors to fibril formation were detected that were perhaps
even more toxic than fibrils (60, 61). In addition, oligomer populations, as detected with
oligomer-selective antibodies, correlated better with pre-mortem dementia (1-5, 45-46). Early
research led many to believe oligomers were pre-cursors to Fibril formation, but today
oligomers are more widely accepted to form early and before plaque formation (33-35).
2.2 Introduction
As the field shifts toward studying oligomers as the source of neurodegenerative
amyloid diseases, a whole new set of questions and complications have emerged. Compared to
their much larger counterparts of amyloid fibrils, oligomers have proven to be significantly
more elusive. Some techniques do exist to detect amyloid oligomers namely, atomic force
microscopy (14), and immunostaining with conformation-dependent anti-oligomer antibodies
(15,16). However, these techniques have low temporal resolution making them poor
candidates for studying oligomer growth kinetics. A common assay for detecting amyloid fibrils
and for monitoring their growth kinetics is to use Thioflavin-T (ThT). This dye dramatically
increases its fluorescence upon binding to amyloid fibrils (6-8). While Thioflavin-T has some
oligomer sensitivity, its fluorescence is typically dominated by its fibril response. Therefore,
Thioflavin-T can only provide limited insights into oligomer formation in vitro, and the role they
might play during fibril formation (9). Ideally one would like to identify dyes that have a strong
selectivity for oligomers over fibrils to act as a companion to Thioflavin-T. With ThT’s selectivity
5

towards fibrils, a dye with selectivity towards oligomers would allow to identify which
aggregate species form when during amyloid formation.
While monitoring oligomer growth kinetics is an important aspect of amyloid research,
oligomer detection would be a critical step towards diagnosing and monitoring amyloid
diseases. Early diagnoses of neurodegenerative amyloid diseases are particularly elusive as
symptoms can be indistinct and often lead to misdiagnoses. If oligomers are indeed the main
culprit for these diseases, finding a technique to detect them in vivo would alleviate the
challenges of diagnosing. Many of the current methods to detect oligomers, such as antioligomer antibodies, are unsuitable for in vivo screening of oligomers. A potential oligomer
selective fluorescent dye however, could be modified to work with already existing in vivo
detection methods such as PET-MRI.
2.3 The basis for a dye screening assay: “Critical Oligomer Concentration”
I proposed an efficient in vitro assay for screening dyes for potential selectivity towards
globular oligomers. As amyloid protein for this screening assay I used the readily available
protein hen egg-white lysozyme (HEWL). HEWL is made of 129 amino acids and has a relatively
small molecular weight of 14.3 kDa (21,22). HEWL has been used widely as a model amyloid,
mainly for its structural similarities with human lysozyme, and for its readily availability and
affordability. Both Human and chicken lysozyme are well known to form amyloid aggregates
under acidic solution conditions. What makes HEWL ideal for our assay is that our lab has
shown that HEWL amyloid assembly, upon crossing a well-defined “critical oligomer
concentration” (COC) , switches from rigid fibril formation in the absence of oligomer formation
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in the lag phase to one generating a rapidly increasing population of metastable globular
oligomers (17, 18). Crossing this COC also correlates with a sharp transition in ThT kinetics from
the ubiquitous “sigmoidal” growth kinetics of nucleated polymerization to a lag-free bimodal
kinetics. The initial phase of this bimodal growth is dominated by gO/CF formation while the
secondary upswing indicates RF nucleation and growth. Below the COC, HEWL grows RFS
aggregates with a distinct lag phase before the start of growth. Growing fibrils in the absence
(sigmoidal) or presence (biphasic) of significant populations of oligomeric species by simple
changes to either protein or salt concentration forms the basis of our oligomer dye screening
assay. My former lab member Tatiana Miti had mapped out the protein and salt concentration
space to clearly identify the transition between these two types of amyloid assembly regimes.
By monitoring dye kinetics to HEWL amyloid growth below and above the COC allows rapid
determination whether a given fluorescent dye responds only to the initial gO/CF or
subsequent RF phase of amyloid growth.
2.4 Sigmoidal vs Biphasic HEWL growth kinetics
Using the above mentioned phase space, we picked out solution conditions that either
fell well below or well above the COC. Typically, four solution conditions would be prepared
with HEWL concentration varying across the COC and with NaCl concentration fixed at 400 mM
NaCl. 15 M ThT was added to each sample. Solutions were placed in a 96-well plate to be
incubated at 52 C, i.e. above the denaturation temperature for HEWL at pH 2 as partial
unfolding is necessary for amyloid aggregate formation.
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A

C

B

D

24 h

24 h

94 h

94 h

144 h

Figure 2.1: Sigmodial vs Biphasic ThT Kinetics
Amyloid growth kinetics of HEWL, recorded with ThT, displaying either (A) sigmoidal (21 µM HEWL)
or (C) biphasic (350 µM HEWL) growth kinetics (pH 2, 52 C, 400 mM NaCl). Second panel in (A) are
same data displayed on a semi-log scale to highlight the flat baseline. Spikes in the biphasic traces
mark times samples were collected for imaging. AFM images of aggregate morphologies observed
during (B) sigmoidal vs (D) biphasic growth of HEWL at the indicated time points. False color height
scale: 3 nm. Figure from Barton et al. Biomolecules Sep. 2019

ThT fluorescence was monitored in the plate reader for several days in order to record
growth kinetics. At higher protein concentrations, above the COC (Figure 2.1C), we see an
immediate onset of growth corresponding to formation of globular oligomers and curvilinear
fibril (gO/CFs). Eventually ThT kinetics reaches an initial plateau which is followed by a second
upswing indicating nucleation and growth of rigid fibril (RFs). This represents the
aforementioned biphasic growth kinetics. At lower protein concentrations, i.e. below the COC
(Figure 2.1a), we see a distinct lag phase. During this lag phase no metastable globular
oligomers are detectable, giving us the previously mentioned sigmoidal shape growth kinetics.
The morphologies of the associated aggregate species were confirmed with AFM imaging at a
8

few relevant time points during amyloid growth, mostly taken at 24 hour intervals. The gO/CFs
observed during biphasic growth have the morphologies consistent with those of toxic
oligomers by other groups (19). It is this sharp change from sigmoidal to biphasic kinetics,
combined with the homogenous population of fibrils vs oligomers during sigmoidal vs. earlystage biphasic growth that serves as the basis for my dye screening assay.
2.5 Secondary structure of HEWL aggregate
Fourier transform infrared spectroscopy (FTIR) is a common technique to determine the
secondary structure of proteins. It has been shown that certain absorption wavenumber peaks
correspond to specific secondary structures in proteins. The limited set of secondary protein
structures gives rise to regions with strong absorption commonly referred to as bands. In
particular, the Amide I band (1600- 1700 cm-1) has extensively studied in the amyloid field and
has proven to be a good indicator of proteins' secondary structure. This band arises mostly
from molecular vibrations of the double bond between a carbon and oxygen atom. While the
exact locations of these peaks vary marginally between proteins, the Amide I band contains
several peaks that correspond to anti-parallel or parallel β-sheets, β-turns, α-helices and
disordered regions. It has already been shown that amyloid fibril and oligomers will display
specific changes to their secondary structure from the monomeric form of the protein (55).
Generally, a rather large uptick in beta sheets is observed as well as a smaller increase in antiparallel beta sheets. This expected change in secondary structure is a strong indication that a
protein aggregate formed is an amyloid.
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A

B

Figure 2.2: FTIR spectra of HEWL monomers, CFs and RFs
(A) Peak-matched FTIR absorption spectra of the Amide-I band for HEWL monomers and isolated
CFs and RFs at pH 2. CFs and RFs show a prominent peak in the characteristic amyloid band
between 1630 and 1610 cm-1. Yet their peak wavenumbers are slightly but reproducibly shifted with
respect to each other. (B) CF and RF differences spectra obtain after subtraction of monomer
spectrum in (A). Figure from Barton et al. Biomolecules Sep. 2019

To confirm that the above gO/CFs match the characteristics of toxic oligomers observed
in amyloidoses, determined their FTIR spectra after isolating them from their monomeric
background. Towards that end, RFs or gO/CFs samples were centrifuged at 15,000 g’s overnight
and resuspended the pellet in their respective growth buffers. This process was repeated at
least 3 times in order to sufficiently purify the aggregated protein from monomers. The
underlying secondary structure of these isolated aggregate samples were then checked with
FTIR. The Amide 1 bands visible in figure 2.2 show that both RFs and gO/CFs have a noticeable
peak in the 1630 cm-1 to 1610 cm-1 region. This is the aforementioned expected diagnostic for
amyloid beta sheet formation (20). While both RFs and gO/CFs have a peak in the characteristic
amyloid band between 1620-1630 cm-, they are notably distinct from each other. This is
particularly noticeable in Figure 2.2 B, where the FTIR spectrum of monomers was subtracted
10

from both of our aggregate FTIR spectrums. The resulting difference spectra nicely emphasize
the prominent increases in amyloid beta sheet content in both fibril and oligomer aggregate
species. But the spectra also show a small, but reproducible difference in the exact location of
the beta sheet absorption peak between CFs and RFs: CFs have their amyloid beta sheet peak at
1618 cm-1 and RFs at 1624 cm-1
2.6 Screening of dyes for amyloid aggregate response
The method of growing distinct, homogenous aggregate populations under very similar
growth conditions allowed me to screen dyes for potential selectivity for oligomers over fibrils.
Protein solutions were prepared with a fixed salt concentration and with protein
concentrations varying across the Critical-oligomer-concentration boundary (COC), where this
sharp transition from sigmodial to biphasic kinetics occurs
As shown previously, below the COC only rigid fibrils grow, allowing us to measure a
new dye's response to rigid fibril formation. Above the COC, gO/CFs initially grow to a plateau,
providing us a region to observe a dye's response to oligomer and curvilinear fibril formation.
Each of these protein solutions was divided into multiple test tubes and a fluorescent dye was
added in preparation for fluorescent growth kinetic measurements in a plate-reader. Identical
solutions, but with 15 µM ThT added, were used as a reference to confirmed the sigmodial
kinetics below and biphasic kinetics above the COC. Typically, three other dyes in addition to
ThT could be accommodated on a 96-well plate for screening under the same growth
conditions. Typical concentrations for novel dyes were 5-10 M. Growth solution were
incubated at 52 C in a 96-well plate for several days. Figure 2.3 shows an example of a plate
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where I measured kinetics responses of (A) thioflavin T, (B) the amyloid dye X-34, (C) acridine
orange and (D) acid fuchsin.

A

B

C

D

Figure 2.3: Fluorescence kinetics during sigmoidal and biphasic HEWL amyloid assembly for various
fluorescent dyes
Kinetics responses of (A) thioflavin T, (B) the amyloid dye X-34 (λex = 370 nm, λem = 482 nm), (C) acridine
orange (λex = 495 nm, λ em = 532 nm), and (D) acid fuchsin (λex = 560 nm, λem = 590 nm) to amyloid
growth of HEWL at the indicated concentrations (in mg/ml) and under fixed solution conditions (pH 2,
52 C, 450 mM NaCl). Orange (0.3 & 0.6 mg/ml) vs. blue traces (2 & 4 mg/ml) represent sigmoidal vs.
biphasic growth conditions. Black traces are dye controls recorded from buffer solution. For overall
comparison, ThT traces are displayed on a linear scale, which obscures its weak biphasic response. Dye
concentrations were 15 µM. Sharp initial transients result from the temperature dependence of dye
fluorescence upon heating to 52 ºC. Figure from Barton et al. Biomolecules Sep. 2019

2.7 A possible oligomer specific dye
Through our screening of dyes, we eventually identified the dye Crystal Violet as a
promising candidate for an oligomer selective dye. Crystal violet has a fluorescence excitation
and emission peak at 590 nm and 620 nm, respectively. We ran this dye through the same
screening assay and plotted the fractional change in fluorescence (F/F 0) in order to better
compare its affinity for gO/CFs vs. RFs to that of ThT (Fig. 5A).
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A

B

C

Figure 2.4: Crystal Violet as Oligomer-Selective Dye (OSD)
(A) Fractional change of 15 µM ThT (open symbols) vs. 5 µM crystal violet (filled symbols) fluorescence
during sigmoidal vs. biphasic amyloid assembly (350 µM HEWL, pH 2, 52 C) in the presence of either
150 or 400 mM NaCl) (B) ThT (15 µM) kinetics of HEWL undergoing sigmoidal fibril growth in the
presence of increasing concentrations of CV. (C) Correlation of fractional CV vs. ThT augmentation
during biphasic vs. sigmoidal growth. During the oligomer-dominated phase of biphasic kinetics,
fractional changes of CV and ThT fluorescence are in lock step and of comparable magnitude. In
contrast, CV becomes essentially unresponsive to the second, fibril dominated phase. During
sigmoidal fibril growth CV barely increases 1.5-fold compared to the nearly 100-fold fluorescence
increase of ThT. Upon aligning the (noise-limited) CV traces with the upswing in ThT, their responses
are strictly linearly correlated in time. Figure from Barton et al. Biomolecules Sep. 2019

During the initial phase of biphasic growth, CV has a response to gO/CFs comparable to
ThT. However, CV remained unchanged, or declined slightly, upon the onset of rigid fibril
formation. Below the COC CV had a much weaker response to rigid fibril growth than ThT, likely
explaining its lack of any noticeable increase to the onset of rigid fibrils when above the COC.
We also correlated the CV fluorescent signal to ThT’s under both biphasic and sigmodal growth
conditions (Fig. 2.4 C). The linear correlation during sigmodal growth and the first phase of the
biphasic kinetics indicate that the amyloid assembly kinetics reported by either dye are
identical, albeit with different sensitivities. The kink in this correlation upon the onset of fibril
13

formation during biphasic growth, in turn, highlights the dramatic difference in the sensitivity to
RFs by ThT vs CV.

A

B

5 hrs

28 hrs

52 hrs

97 hrs

Figure 2.5: Evolution of Amyloid Aggregate Morphology during Biphasic Kinetics
(A) Staggered incubation of 350M HEWL undergoing biphasic amyloid growth at pH 2, 52 C and
450 mM NaCl, recorded simultaneously with 15 M ThT () and 5 µM CV (). Fresh solutions were
added to the 96 well plates at the moments indicated by the arrows. Corresponding total incubation
periods are shown next to each arrow.(B) AFM images of aliquots imaged from wells incubated for
the indicated time periods. While the initial phase of biphasic growth indicates the presence of gOs
and increasing numbers of CFs, the late phase shows the simultaneous presence of RFs and CFs,
often in direct contact with each other. The false color scale indicates aggregate heights. All images
are 3 µm on a side. Figure from Barton et al. Biomolecules Sep. 2019

One potential explanation for CV’s lack of biphasic kinetics above the COC could have
been that CV actively inhibits rigid fibril formation. I checked for this by measuring CV and ThT
in the same wells, while also using a series of different CV concentrations (Fig. 2.4 B). As shown,
for concentrations comparable to our previous experiments, there is no discernable difference
in ThT kinetics. At the larger CV concentrations ThT has a slightly reduced signal, however the
14

time scale of growth is unchanged. This decrease in ThT fluorescence is then likely explained by
some level of competitive binding to fibrils between CV and ThT. In our biphasic kinetics, once
rigid fibril formation begins, CV has mostly plateaued, and with its strong affinity to gO/CFs this
likely means that gO/CFs persist during the nucleation and growth of RFs. To confirm this, we
used AFM imaging on aliquots sampled from a 96-well plate incubated under growth
conditions. Identical solutions were added every 24 hrs. For several days, and only a couple
hours on the last day prior to stopping the experiment. This staggered incubation protocol
allowed us to image samples at different stages of the reaction but at the same time point, with
AFM (Figure 2.5). These images show the aggregate species expected for each stage of our
biphasic kinetics. In addition they show that residual gO/CFs persist well into the second
plateau phase. In related experiments we had previously observed that gO/CFS persist for
weeks into the apparent plateau phase of fibril formation. This suggests that the second ThT
"plateau" during biphasic growth is not an indication of the "reaction endpoint" of fibril
formation. Instead, it indicates the depletion of free monomers by RFs and the subsequent very
slow process of gO/CF depolymerization and subsequent incorporation of the released
monomers into RFs.
2.8 Separating biphasic kinetics into its gO/CF and RF components
As our AFM images show, the two distinct aggregate species have some period of
overlap during biphasic kinetics. In addition, we have shown that gO/CFs act as inhibitors of
rigid fibril nucleation (22). The identification of the predominately gO/CF sensitive dye CV vs.
the predominately RF-sensitive dye ThT opens up the possibility of decomposing amyloid
growth kinetics into its underlying RF and gO/CFs components during biphasic region.. To do so
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I used protein concentrations spanning across the COC to get biphasic and sigmoidal kinetics. In
Figure 2.6C, when accounting for the difference in fluorescence enhancement of CV vs. ThT
upon binding to RFs, it is clearly shown that CV and ThT have identical growth kinetics in the
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Figure 2.6: Correlation of CV and ThT Kinetics.
(A,B) HEWL amyloid formation (pH 2, 450 mM NaCl, T= 52 °C) at concentrations below (orange) and
above (blue) the COC, simultaneously monitored with (A) ThT (15 M) and (B) CV (5 M). Traces are
the average of three recordings from separate wells. (C,D) Superposition of the CV (solid lines) and
ThT (dashed lines) responses, after matching the CV data using the -factor determined in E and F,
respectively. Subtracting the matched CV from the ThT trace yields the orange sigmoidal trace in (D).
(E,F) Correlation of the fractional changes of ThT vs. CV responses during (C) sigmoidal vs. (D) biphasic
growth kinetics. The -coefficient indicates the ratio of the CV vs thT response amplitude in the linear
regime of each plot. Figure from Barton et al. Biomolecules Sep. 2019

sigmodal RF regime, but with of course significantly differences in sensitivty. Similarly, the
difference in fluorescent intensity was accounted for in the biphasic regime and shows CV and
ThT changes correlate perfectly until a sudden divergence. Fig. 2.6 D shows the ThT trace
resulting after subtracting the amplitude-matched CV trace. This trace shows a clear lag period
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with the expected sigmoidal RF kinetics, given us a nearly perfect decomposition of gO/CF and
RF growth kinetics during biphasic kinetics.
2.9 Screening of more fluorescent dyes
While crystal violet has shown selectivity towards oligomers it is possible that its
selectivity is limited to the specific pH, temperature, and other specific solution condition used
in our assay. It may be important to identify a number of other oligomer selective dyes in order
to combat scenarios where specific solution conditions may render one oligomer dye more
useful than another. I continued to screen for other possible candidates of oligomer selective
dyes. Other dyes I had screened included the amyloid dye X-34, Ethidium Bromide, and Hoechst
33342. Ethidium Bromide and Hoechst 33342 are common dyes used for cell staining.
Our lab has run several cell toxicity experiments using theses dyes and has observed
them binding to the aggregates that were put on these cells. While several of these dyes had
some possible selectivity toward and aggregate species none of them were quite as selective as
crystal violet, except perhaps for methyl violet which is similar to crystal violet in both its level
of selectivity as well as chemical structure. Our lab still continues to screen dyes to hopefully
find more promising selective dyes
2.10 Shifting of dye screening assay to near-physiological conditions
2.10.1 Amyloid Beta
While CV has proven to be fairly reliable oligomer indicator under the acidic growth
conditions for HEWL amyloids it would be helpful to find an oligomer selective dye that works
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with a disease relevant protein under near-physiological conditions. Dyes are well known to
have varying dependences on solutions conditions and testing dyes under conditions similar to
physiological means the dyes are more likely to hold up their oligomer selectivity as an in vivo
detector of oligomer. With that in mind there are a number of possible ways to improve this
dye screening assay. Namely, an attempt to shift it towards a more disease relevant protein, as
well as a more biological pH.
One of the changes I made to the assay was to use amyloid beta peptide instead of
HEWL as the protein in the assay. Aβ is intrinsically disordered and has two main variants Aβ 140 and Aβ 1-42. It is believed to be the underlying or initial culprit for Alzheimer’s disease (2325). Our lab has shown that the same transition from sigmoidal to biphasic kinetics upon
increasing protein concentration, is present in amyloid beta peptide (Aβ). This illustrates how
the same methodology of using sigmodial vs biphasic kinetics to screen dyes for potential
selectivity toward oligomers would work for amyloid beta as well would work
The in vitro growth conditions for this transition were pH 7.4 with either no salt or
physiological NaCl concentration, minimizing the risk that a dye identified in this assay is
unresponsive in vivo. Ideally I would check all of our potential oligomer selective dyes under
these conditions, as dyes that hold up as oligomer selective under these conditions would be
very promising candidates for in vivo detection of oligomers. However, this protein is
expensive and using it for our dye screening assay would likely be reserved for only our most
promising dye candidates.
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Figure 2.7. Growth kinetics for Aβ1-40 and Aβ1-42
Transition from sigmoidal to biphasic kinetics and associated gO/CF formation for Aβ1-40 and Aβ1-42.
(a) Transition in Aβ40 growth kinetics from pure sigmoidal (orange) to biphasic (blue) kinetics (pH 7.4,
no salt). (b) Same as (a) but for Aβ1-42. Semilog plot emphasizes weak ThT response during gO/CF
phase. (c) ThT fractional change during Aβ1-40 growth in physiological saline. Notice the significant
increase in gO/CF amplitude relative to panel (a). (d–f) TEM images of samples of (a)—Aβ1-40 RFs
following sigmoidal growth at 50 μM (d) versus biphasic growth at 150 μM, with gO/CFs formed within
1.5 days, and (e) mixtures of gO/CF and RFs after 6 days (f). Figure from Barton et al. Biomolecules Sep.
2019

2.10.2 pH 5 HEWL Assay
For more preliminary testing of dyes, I planned to move the HEWL assay closer to
physiological pH thereby preserving the convenience and cost effectiveness of our current dye
screening assay, versus the much more expensive Aβ, but still improving the similarity to
physiological conditions. This meant finding sigmoidal and biphasic growth conditions for HEWL
when approaching physiological pH. I started this process by increasing the pH from 2 to 5, as a
stepping stone for the eventual goal of pH 7. The denaturation temperature of HEWL at pH 5
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was found to be roughly 63°C. A plate was prepared with several protein and salt conditions
and was incubated at 65°C overnight with continuous agitation at 700 rpm.
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Figure 2.8: pH 5 HEWL Fibril Growth
HEWL amyloid fibril formation (65 C, 700 rpm, 1 mg/ml, 200 or 400 mM NaCl, at pH 5. Figure (A) shows
the ThT growth kinetics for 1 mg/ml of HEWL with varying salt concentrations. Figure (B) is a TEM image
taken at the endpoint of one of the 1 mg/ml,400 mM NaCl traces in (A). (A,B) Show the expected
sigmoidal growth behavior and morphology of amyloid fibrils, albeit with the latter significantly more
bundled than the fibrils grown at pH 2.

Finding conditions at this pH that would give the expected biphasic behavior, or finding it at pH
7, proved to be challenging and is an ongoing goal of this dye screening project. If we find the
transition of kinetics for HEWL at pH 5 or pH 7 we can continue to use our cheap model protein
for initial dye screening. At the same time we would be improving the relevance of any of the
oligomer dyes we find to detecting amyloid disease oligomer in vivo.
2.10.3 Human Lysozyme
Another potential improvement attempted to be made to the dye screening assay was
to use human lysozyme, the amyloid protein behind lysozyme amyloidosis, instead of HEWL.
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Lysozyme amyloidosis is a disease in which large amounts of plaques of lysozyme accumulate in
organs within the body. These amyloid structures often result in organ dysfunction leading to a
variety of symptoms depending on the affected organ. Since HEWL has roughly 60% of the
same homology and nearly identical secondary structure to human lysozyme, exploring
lysozyme amyloidosis and applying our dye assay to HuLys, in theory, is a convenient avenue to
make the dye assay more disease relevant.

The first step was checking HuLys for the same sigmoidal and biphasic behavior that was
observed in HEWL under acidic conditions. A plate was prepared with similar solution
conditions to one of the HEWL plates that would cross the COC by varying protein
concentration at a fixed salt concentration. I noticed however that HuLys did not behave as
similar to HEWL as expected. Most notably, I was unable to get HuLys to display the same
biphasic kinetics that we observed in both amyloid beta and HEWL. Once suitable conditions for
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this assay are found that do display biphasic kinetics one could begin checking the most
promising dye candidates from the HEWL assay with HuLys. Ideally, we would like to show that
any oligomer sensitive dyes we find, like Crystal Violet, are generally selective to oligomers
formed by various amyloid proteins, and not just those by HEWL
2.11 Discussion
Using the clear transition from sigmoidal to biphasic growth kinetics in HEWL, I
developed a straightforward assay for screening dyes for their fluorescence responses to
different aggregate species. Utilizing this assay I screened a number of dyes and identified the
oligomer sensitive dye crystal violet. However, it is known that dye fluorescence can have
strong dependence on pH, temperature, ionic strength, ion identity and, perhaps, oligomer
identity. For example, I have observed that the amyloid dye ThT loses its fluorescence after
about 2 days upon incubation at elevated temperatures (> 40 C) at pH 7. Ideally, one would
investigate dyes for multiple proteins under physiological growth conditions.
I’ve provided evidence that transitioning this assay to more physiological conditions is
possible. The model protein HEWL itself can undergo amyloid formation at elevated pH, albeit
at a much higher denaturation temperature. Additionally, Human Lysozyme was shown to form
amyloid aggregates under similar conditions to HEWL. Most importantly, Aβ40 and Aβ42 were
shown to have this same transition from sigmoidal to biphasic kinetics at physiological pH and
ionic strength. This suggests that one could readily extend this assay to amyloid beta peptides,
or other disease relevant proteins. Dyes that appear oligomer selective under physiologically
growth conditions with amyloid beta peptide would be excellent candidates for an oligomer
detector in both ex and in vivo
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A more challenging question is whether the early-phase oligomers grown with HEWL
above the COC are the most disease-relevant oligomer species. The second part of my thesis
research is focused on this question.
2.12 Materials and Methods
2.12.1 Preparation of HEWL
Two times recrystallized, dialyzed and lyophilized HEWL (Worthington Biochem. Corp.,
Lakewood, NJ) was dissolved in 25 mM KH2PO4 pH 2 buffer and then placed in a water bath at
42 C for a few minutes in order to completely dissolve the protein. Protein solutions were
filtered with a 220 nm syringe filter and mixed with the appropriate proportions of 0 mM NaCl
and 1 M NaCl buffer solutions to reach specific NaCl conditions for our assay. By fixing the NaCl
concentration, typically at 400 or 450 mM, we could cross the COC for oligomer formation by
increasing protein concentration. This approach minimized changes in dye fluorescence due to
ionic strength or ion-specific effects. Concentrations of HEWL samples were determined from
UV absorption measurements at 280 nm (α280 = 2.64 ml mg−1 cm−1 ). UV absorption
measurements were taken with a DeNovix DS-11-FX UV spectrophotometer.
2.12.2 Preparations of Thioflavin-T and other dye stock solutions
Thioflavin-T stock was prepared by dissolving it in DI water to 1-2 mM and filtering it
with a 220 nm syringe filter. Other dyes stocks were prepared similarly unless they were not
soluble in water, in which case they were dissolved in DMSO. Concentrations were measured
using the same spectrophotometer and the dye’s published absorption coefficients. For dyes
dissolved in DMSO, an additional control was incorporated into the dye screening protocol by
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adding the largest DMSO concentration to a HEWL growth solution together with ThT. This
indicated whether DMSO itself would alter the assembly behavior.
2.11.3 Fluorescent spectra measurements
A FluoroMax-4 spectrofluorometer (Horiba Yobin-Ivon, Piscataway, NJ) was used for
measurements of fluorescent spectra of dyes. For a given dye excitation and emission spectra
were taken to determine the appropriate wavelengths for fluorescent measurements. Typically,
an optimal excitation and emission peak was determined for any dye under three conditions: in
pH 2 buffer, at pH 2 with monomeric forms of protein present, and at pH 2 with isolated HEWL
rigid fibrils present.
2.12.4 Fluorescence measurements of growth kinetic
Fluorescent kinetic measurements were performed using one of two plate readers: a
SpectraMax M5 grating based fluorescence plate reader (Molecular Devices, San Jose, CA) or d
a Fluorostar Omega plate reader (BMG Labtech, Cary, NC). Typically, 270 µL of a growth
solution was added to a well in 96-well glass bottom plates (Cellvis, Mountain View, CA) and
monitored at growth temperatures. In most cases three identical wells were prepared for each
solution condition. Typically, fluorescent readings were acquired every 15-20 minutes for
several days in order for growth kinetics to reach a plataeu. To accelerate the growth kinetics,
plates were gently agitated using pulse shaking at 100 rpm for 3 seconds before each
measurement.
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2.12.5 Atomic Force Microscope.
Samples were typically diluted 10-100 fold depending on solution conditions. Then 40 μl of the
diluted sample was deposited onto a freshly cleaved mica sheet for 3- 5 minutes. Droplets of
water were added to mica and then removed in order to wash away excess salt. These mica
sheets were then dried using nitrogen gas. Aggregates deposited on mica imaged were imaged
in air with a MFP-3D atomic-force microscope (Asylum Research, Santa Barbara, CA) using PFPFMR-50 (Nanosensor, Neuchatel, Switzerland) silicon tips with nominal tip radii of 7 nm.
2.12.6 Electron Microscope images
Samples were diluted in DI water to concentrations ranging between 10-0.1 µM
depending on the specific sample. A 5 uL drop was then added to Formvar/carbon film coated,
200 mesh copper grids (Electron Microscopy Science). This droplet was left on the grid for 2-10
minutes and then blotted from the grid with filter paper. The grid was washed repeatedly,
mostly to remove excess salt, by adding a 5 µL drop of water to the grid and blotting it with
filter paper after a few seconds, repeating this process for 3-10 times depending on amount of
salt in the sample solution. A stock of 8% w/v stock solution of uranyl acetate was used to
negatively stain these grids for imaging. A 5 µL droplet of our uranyl acetate solution would be
added to the grids and blotted away after 30 seconds. The DI water washing technique used to
remove salt was then repeated to remove any remaining uranyl acetate from the grid. Grids
were imaged using a FEI Morgani transmission electron microscope at 60 kV with an Olympus
MegaView III camera.
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2.12.7 Fourier Transform Infrared Spectroscopy Measurements
Fourier Transform infrared Spectroscopy (FTIR) measurements were taken on a Bruker
Optik Vertex 70 (Ettlingen, Germany) spectrometer. Typically, 27 uL of solution were added to
the top of silicon crystal used for the ATR setup of this instrument. Background scans of the
solvent solution were taken over 1200 scans at 2 cm-1 resolution. Sample spectra would be
measured from 3000 to 1000 cm-1 wavenumbers, with 600-1000 scans taken depending on the
intensity of the signal. FTIR spectra in the Amide I Band between 1600 to 1700 cm -1were
normalized to either their peak values or their total area under the peak. Difference spectra for
aggregate samples were created by subtracting the normalized monomer IR spectrum from the
spectrum of the amyloid aggregate sample.
2.12.8 Fast protein liquid chromatography
A Superdex 75 10/300 GL column (GE Healthcare) was connected to an ATKA-pure
purification protein system pump (GE Healthcare) and was washed for 2 column lengths with
water, and then washed with the same buffer as the sample is in. Both of these wash steps
were done with column down flow. Sample were typically injected at 1-2 mg/ml with a total
volume of 300-500 µL into the system. UV absorption was monitored and any observed peaks
were fractionated and collected into test tubes. The column was then cleaned by running two
column volumes of water upward through column followed by 1 -2 column volumes of ethanol.
Column was kept in FPLC unit while filled with ethanol until next uses.
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2.12.9 Human Lysozyme sample preparation
Recombinant and lyophilized Human Lysozyme was purchased from Sigma-Aldrich (St.
Louis, MO). Typically, 100-200 mg of protein was dissolved into DI water and dialyzed with 20
kDa membrane tubing overnight. Water was typically replaced at the 2, 4, 18 and 20 hour time
points of dialysis. . The protein was then lyophilized in FreeZoneTM2.5 Plus (LabConco) Freeze
Dryer. Samples were typical left over 2-3 before collecting the lyophilized powder. This purified
powder was then used to prepare samples in a manner identical to our HEWL sample
preparation.
2.12.10 Amyloid Beta peptide sample preparation.
Roughly 1 mg of Amyloid β peptide (rPeptide) was dissolved in 500 μl of 100 or 150 mM
NaOH and passed through and FPLC with a Superdex 75 10/300 GL column (GE Healthcare).
This column was washed with water and 35 mM Na2HPO4, 5 mM NaOH, 50 mM NaCl at pH
11.The monomers were fractionated and collected from the FPLC. Final monomer
concentrations were measured using UV absorption using 280 = 1490 cm-1. Aβ samples then
had their pH adjusted from 11 to 7.4 by adding 1.5%, by volume, of 1 M NaH 2PO4 .
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Chapter 3 - Toxic Oligomers originating in the Rigid Fibril assembly pathway
3.1 Background
The original amyloid cascade hypothesis for Alzheimer’s disease states that the
formation of amyloid fibrils and plaques is the root cause of subsequent neurodegeneration
and clinical symptoms (26). However, this is at odds the observation that the severity of clinical
symptoms bears little correlation to the amount of amyloid plaques present in the brain post
mortem (27, 28). As previously mentioned, there is now growing evidence that precursors or
intermediate states of fibril formation, such as globular oligomers, may be the main diseasecausing culprit. It is known that many disease relevant amyloid proteins have the ability to form
oligomers, such as α-synuclein, tau and amyloid beta peptide (49, 50, 54, 55). Yet, there is still no
agreement on the disease relevance of oligomers and results in the field often disagree which
aggregate species are cytotoxic. The heterogeneous nature of amyloid aggregation has made it
difficult to determine which aggregate species do form, what their mechanisms of cytotoxicity
or, and which of those mechanisms are most relevant for AD.
Our lab is uniquely equipped to explore how growth conditions affect which types of
amyloid species do emerge during amyloid formation. The ability to aggregate HEWL amyloid
aggregates along one of two distinct assembly pathways gives us the ability to selectively
generate gO/CFs or RFs and study their cell toxicity separately. In addition, by isolating either
gO/CFs or RF from the monomers present via centrifugation we can better characterize the
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spectroscopic and tinctorial properties of these aggregates. By better characterizing our
aggregate species, and forming homogenous aggregate populations, we were able to quantify
the cell toxicity of specific amyloid aggregate species, which has been a shortcoming of similar
studies in the past. While performing these cell toxicity experiments, we also uncovered yet
another type of oligomer that displayed the highest level of toxicity of any amyloid species we
have studied (Figure 3.2). We therefore set out to elucidate the origin of this new species and
provide an at least preliminary characterization of its biophysical and immunological properties
3.2 Preliminary Toxicity Data
3.2.1 Preparing and isolating HEWL aggregate species for cell toxicity assay
In order to conduct cell toxicity experiments gO/CFs and RFs were prepared in DI water,
adjusted to pH 2 by the addition of small amounts of hydrochloric acid. This differs from my
previous described method of preparing aggregates in pH 2 Potassium Phosphate buffer
because preliminary cell toxicity results showed that this buffer was toxic to cells. While RFs,
were grown at 50 mM NaCl concentration (below COC), gO/CFs were generated by incubating
monomers with 250 mM NaCl (above COC). For both above and below COC conditions HEWL
concentration was 20 mg/ml and solutions were incubated at 52°C in a heat block. RF samples
were incubated between 6-9 days while gO/CF samples were incubated for only 2-4 hours, with
their growth monitored with dynamic light scattering. These aggregates were then isolated
from monomers by spinning them at 15,000 g overnight and resuspending their pellets in pH
adjusted water. This process was repeated 2-4 more times until the supernatant contained a
negligible amount of residual monomers. Morphologies of these samples were then checked

29

with TEM (Figure 3.1). Once isolated, aggregates were transferred to pH 7.4 cell media. Upon
transfer these aggregates precipitated into distinct structures: rigid fibrils showed a strong
tendency to bundle into highly organized fibril sheets, as seen in TEM (Fig. 3.1, top row). In
contrast, gO/CFs formed diffuse, fractal-like clusters. We also checked for standard
characteristic of amyloid plaques using optical microscopy (Figure 3.1, bottom two rows ). Rigid
fibrils showed strong Thioflavin S (ThS) fluorescent and birefringence, a staple diagnostic of
fibril amyloid plaques. In contrast CFs show only weak ThS staining and no birefringence,
indicating a lack of long-range order within the CF precipitates.
These distinct differences between RF and CF precipitates under optical microscopy has
an interesting correlation with the types of plaques found in Alzheimer’s patients. Amyloid
beta plaques, present in patients, are typically described as either being neuritic and dense
core, or diffusive. Neuritic/ dense core plaques have strong ThS fluorescence and birefringence,
while diffusive plaques have a weak ThS fluorescence and no birefringence. The origins and
relevance’s of these two types of amyloid plaques are still widely debated, but our results
suggest these different types of plaques may originate from different amyloid aggregate
species.
3.2.2 Cell Toxicity Results
Cell toxicity of various amyloid aggregate species was evaluated using an imaging livedead cell viability assay. This assay used two fluorescent dyes: Ethidium Homodimer, which is a
membrane-impermeable dye that can bind to the nucleus of dead cells, and NucBlue which is
cell permeant and can therefore bind to the nuclei of living cells. Ethidium Homodimer and
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NucBlue fluorescence are excited at 528, and 360nm, and fluorescence collected at 617 nm and
460 nm respectively.

Figure 3.1: Images of Lys amyloid aggregates before and after transferring to pH 7
TEM images before and after transferring isolated RFs and CFs from pH 2 to pH 7 cell media (top two
rows). It also shows bright field, ThS fluorescence and Congo Red birefringence of the same isolated
aggregate species, imaged using optical microscopy (bottom two rows) These optical images resemble
the types of plaque neuritic and diffusive plaques associated with Alzheimer’s Disease. Images of
neuritic and diffuse plaques are taken from Hayne, David & Lim, Sinchun & Donnelly, Paul. (2014).
Chemical Society reviews. 43. 10.1039/c4cs00026a.
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Once aggregates were added to cells, the cells were incubated for three days and cell
viability was determined from the average number of live cells under a given incubation
conditions. Several control solutions are used as reference. Namely, cell media is used as a
negative control, and the apoptotic peptide KLAK as a positive control. In addition, plain growth buffer
(pH 2 buffer + NaCl), and growth buffer with HEWL monomers, as well as the respective supernatants of
each of our isolated aggregates species were used as controls to eliminate any possible effects on cell
viability not originating from the added aggregate species.

Figure 3.2: Cell toxicity data of HEWL aggregates
The above shows the cell viability for both HEWL RFs and CFs, obtained via a live-dead fluorescence
microscope assay. In addition to these two aggregate types, several control conditions are shown,
including the supernatant of the first centrifuge spin to isolate RFs or gO/CFs from smaller aggregates.
Notably, the RF supernatant appeared to be the most toxic condition, while CFs showed only marginal
levels of toxicity.
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The cell toxicity data in Figure 3.2, shows that isolated rigid fibrils were somewhat toxic
to cells. However, it was the supernatant of RFs that was the most toxic. This was surprising as
we assumed that the supernatant of these samples only contained monomeric HEWL, with
perhaps small amounts of fibrils that had not been properly spun down. Since the fresh
monomer control had no discernable toxicity this led us to believe that some other small
aggregate must be present in our RF supernatant. We speculated that these small aggregates
could perhaps be oligomers. Since the gO/CF oligomers grown in conditions above the COC
were marginally toxic, at best, this implied that we had generated an oligomer species different
from those prevailing above the COC. I therefore set out to characterize this new oligomer
species, to determine when and how it emerged during what we had believed was "oligomerfree" fibril growth, and performed some biophysical characterization of these new oligomers.
3.3 Checking for Oligomers in RF SN with DLS and FPLC
I explored a number of techniques to confirm the existence of an oligomeric aggregate
species in the RF supernatant. Initially these experiments focused on detecting assemblies with
a molecular weight or size different from that of the HEWL monomers present in solution. The
supernatant was first checked with dynamic light scattering (DLS) to determine whether it
contained small fibrils that had not been spun down, or some other larger aggregates that
centrifugation didn’t separate from the supernatant. Dynamic light scattering is particularly well
suited for differentiating between monomers and rigid fibrils, since they are several orders of
magnitude different in size. In addition, larger aggregates contribute roughly in proportion to
the square of the molecular weight to the DLS signal and are therefore particularly prominent in
the resulting particle size distribution. The particle size distribution in Figure 3.3a shows the RF
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supernatant as only having a broad peak around 2 nm hydrodynamic radius, which is
characteristic of HEWL monomers. Occasionally a larger peak was observed in DLS
measurements of the RF supernatant, but typically the samples were overwhelmingly
monomeric and any large aggregates that were seen in dynamic light scattering could be
removed by filtering the sample through a 50 nm syringe filter.

Fig A

Fig B

Figure 3.3: Size characterization of Rigid Fibril supernatant
The left (A) shows the DLS trace of the rigid fibril supernatant. There is one peak localized around 2 nm,
typical of our HEWL monomers, this suggests no fragmented rigid fibrils are present. On the right (B) is
UV vs elution volume trace of the same supernatant run through our FPLC size exclusion column, as well
as a pure monomeric sample. The supernatant in FPLC shows tow peaks, one that lines up with the
monomeric peak, and another slightly larger one that we believe corresponds to our fibril derived
oligomers.

Dynamic light scattering however, has very poor resolution for distinguishing between
molecules of comparable hydrodynamic radius, including any potential toxic small oligomers
(<10 monomers) that may be present. I therefore performed fast protein liquid
chromatography (FPLC) on the RF supernatant to check for the presence of any small oligomers.
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The UV trace in figure 3.3b of the eluent shows that the RF supernatant contained no large
aggregates but did show two peaks, a broadened monomer peak near 20 ml and a prominent
oligomeric peak at 16 ml. This confirmed that the supernatant of our fibril samples did indeed
contain a population of small oligomers that had remained undetected using the kinetic assays
(ThT, light scattering) to monitor RF growth below the COC.
3.4 What are the size/molecular weight of these toxic oligomers?
There is some discussion in the field about the importance of the molecular weight of
oligomers regarding their role in Alzheimer’s. Some labs have proposed to separate Aβ
oligomers into two species: essentially nontoxic low molecular weight species and highly toxic
high-molecular weight oligomers (56 kDa oligomers) (31-32,64). Therefore, it was of interest of
us to establish the molecular weight of these toxic oligomers. I therefore calibrated the elution
volume of our FPLC column using a series of reference proteins. A solution was prepared of
equal concentrations of hen-egg white lysozyme (14.3 kDa), trypsin (23.3 kDa), pepsin (34.5
kDa), and bovine serum albumin (66.5 kDa), dissolved in pH 2 adjusted water. The
corresponding elution profile is shown in Figure 3.4. The UV trace peaks of each monomer
protein have different heights, because they were added at the same protein concentration but
have different absorption coefficients. In addition, I have observed that different proteins have
different affinities for sticking to the injection site, the entry filter to the column, or in the case
of lysozyme have a high affinity to interact with the agarose/dextran matrix within the column
itself.
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Figure 3.4: FPLC of protein with varying molecular weight
Above (A) is the FPLC UV trace of a sample mixed with roughly 0.5 mg/ml of HEWL, trypsin, pepsin and
albumin at pH 2 50 mM NaCl (red) and our RF SN (blue) whose largest peak is believed to be our toxic
oligomers. B shows the MW vs elution volume calibration curve, on log-log scale, for the size-exclusion
column under these conditions. The table below lists the molecular weight, in kilo Dalton of each of the
respective proteins.

Table 3.1 Molecular weights of Proteins used in FPLC size-calibration
Shows the molecular weights of the different proteins used in the experiment shown in Figure 3.4

Protein Name

Molecular Weight

Hen-egg white Lysozyme

14.3 kDa

Trypsin

23.3 kDa

Pepsin

34.5 kDa

Bovine Serum Albumin

66.5 kDa
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This calibration of molecular weight in our column provided a rough read-out of the
molecular weight of the oligomers in the RF supernatant. In Figure 3.4, I showed that the RF
supernatant toxic oligomer peak is at roughly 16 mL elution volume, i.e. between that for
pepsin and BSA. This suggests that these toxic oligomers are about the size of a trimer. This also
explains why DLS was unable to separate them from the monomer peak in those particular size
distribution measurement. It is worth noting that elution volume shares a logarithmic
relationship with molecular weight. Using this relationship, I plotted molecular weight vs log
volume of our mixed molecular weight sample and fitted a linear trend to it. This plot shows
that our toxic oligomers are likely trimers with a molecular weight estimated to be ~38 kDa.
3.5 Techniques to Isolate Toxic Oligomers from Monomers
For further characterization of this species of small, toxic oligomers, I needed a way to
isolate them from monomers, similar to how centrifugation has been used to isolate RFs and
CFs from monomers. I was able to use FPLC as a method to fractionally collect the toxic
oligomers from the monomers in the RF supernatant in some of my experiments. However, this
approach has limited yield due to the overall limitation on loading volume for our analytical
FPLC column. Furthermore, for many of my experiments I needed to separate several samples
at once, making FPLC a time-consuming approach.
I therefore tested centrifugal cut-off filters as means for isolating toxic oligomers from
monomers. After the initial "standard" centrifugation to remove rigid fibrils, the resulting
supernatant was passed through a 50 kDa molecular weight cut-off filter at 14,000 g for 15
minutes. Buffer was repeatedly added to the top of the filter, and again spun at 14,000 g for 15
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min. This wash step was repeated three times. I tested this protocol on both the RF
supernatants and fresh monomer samples and measured the concentration of protein that
came through the filter after each spin, as well as what remained at the top of the filter after
the final spin.
Table 3.2: Effectiveness of cut-off filters to isolate TOs
Progressive protein concentration measurements of filtrate during 50kDa cut-off filter centrifugation
protocol. Shown are the residual protein concentrations using either fresh monomers or the RF SN (toxic
oligomer sample). The order of magnitude of more protein collected using this method. In the RF Sn vs
monomer sample shows how well toxic oligomers are collected and isolated via this protocol.

50 kDa cut-off filter of pH 2 HEWL
Monomer

RF SN

Initial Conc.

7.6 mg/ml

7.6 mg/ml

1st spin (bottom filtrate)

7.1 mg/ml

6.7 mg/ml

2nd spin (bottom)

1.5 mg/ml

2.1 mg/ml

3rd spin (bottom)

0.2 mg/ml

0.5 mg/ml

(top residue) Collected
after third wash

0.2 mg/ml

2.1 mg/ml

Both monomer and toxic oligomer samples started this separation protocol at a
concentration of 7.6 mg/ml. The concentration left at the top of the filter after three washes
was 0.2 mg/ml for monomers and 2.1 mg/ml for the toxic oligomer sample. As expected,
significantly more protein remained at the top of the cut-off filter for the toxic oligomer sample.
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This method gives us roughly a 10:1 ratio of toxic oligomers to monomers after three spins. For
all following experiments samples were therefore washed no less than three times to isolate
toxic oligomers from monomers.
As mentioned above, the transfer of toxic oligomers from pH 2 to pH 7 for cell
experiments caused noticeable precipitation. If this precipitation was solely due to toxic
oligomers, then pH 7 transfer would provide another way to isolate toxic oligomers from
monomers. However, I needed to determine whether hydrolyzed monomers, which were also
present in solution, could contribute to the precipitates at pH 7

Figure 3.5: Precipitation of Rigid fibril supernatant
The above shows a picture of an RF SN (toxic oligomers still mixed with hydrolyzed monomers) and
isolated hydrolyzed monomers of the same sample, after being transferred to pH 7. Similair levels of
precipitation are also observable with the other two aggregate types (RFs and CFs)Hydrolyzed
monomers had no visible precipitates. This proposes pH transfer as a possible method of isolation of
these toxic oligomers to the monomeric background

To check whether my precipitate was formed by toxic oligomers, monomers or a
mixture of the two, toxic oligomers and monomers were separated using the above mentioned
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cut-off filter separation protocol. Once separated, the concentration of both monomer and
isolated toxic oligomer sample was measured, and diluted to the same concentration in pH 2
buffer. My monomer and toxic oligomer samples were then diluted 10 fold into pH 7 sodium
bicarbonate buffer. After pH 7 transfer visible precipitation had formed in the toxic oligomer
sample while the sample containing just hydrolyzed monomers displayed no visible
precipitation. Samples were checked periodically for several days to make sure that
precipitation had not simply occurred at a slower rate with the monomer sample. Some timedependence of precipitation was often observed for even the toxic oligomer samples, in
particular if the concentration of toxic oligomers was low. Later experiments however, would
show that while my toxic oligomer sample is isolated from monomers using this method, a
small concentration of toxic oligomers may still exist within the “hydrolyzed monomer” sample
With confirmation that the precipitates at pH 7 were predominately due to the
precipitation of oligomers, transferring toxic oligomers to a higher pH could serve as a method
of isolating the aggregates from the hydrolyzed monomers. Albeit, precipitation did not appear
to be reversible upon transfer back to pH 7. Hence this approach is only useful for
concentrating toxic oligomers at pH 7. Other amyloid aggregates showed similar precipitation
behavior upon transfer to pH 7 and were characterized during the previously described cell
culture experiments. For subsequent experiments, the protocol used for isolation of TOs was
the above described use of 50 kDa molecular weight, since it was often preferable to have the
TOs still under growth conditions and for them to still be soluble in solution.
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3.6 Amyloid Characteristics of Toxic Oligomers
3.6.1 TOs Secondary Structure
The above experiments provided solid evidence that some small aggregates were
present in the RF supernatant. To confirm that these aggregates were in fact amyloids I
investigated the secondary structure content of these aggregates using FTIR. Specifically I
explored whether the FTIR spectra from toxic oligomers, like other amyloid aggregate species,
have a peak in the characteristic amyloid beta-sheet range between 1610 and 1630 cm -1. I
prepared toxic oligomers using the standard RF growth and separation protocol and measured
their FTIR absorbance spectrum (Figure 3.6). Samples were also diluted ten-fold in pH 7 sodium
bicarbonate buffer, and measured the absorbance spectrum after pH transfer.

Figure 3.6: FTIR of Rigid Fibril Supernatant
(left) Amide I IR spectrum for fresh monomers, and toxic oligomers before and after transferring to pH7.
(right) Difference spectra obtain by subtracting monomers spectrum from oligomer spectrums at either
pH. Peaks were normalized by area under the amide I band prior to subtraction. Spectrums show
expected characteristic cross-beta sheet peak (~1620 cm -1) in RF SN, as well as possible enhancement in
anti-parallel beta sheet structure (~1690 cm-1)
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The toxic oligomers show a characteristic amyloid beta sheet peak near 1620 cm -1 in the
Amide I band, both at pH 2 after transfer to pH 7. Perhaps even more importantly, the toxic
oligomers have an additional peak in the anti-parallel beta sheets regime around 1680 cm -1. I
had measured this anti-parallel structure in our globular oligomers before but not as strongly as
it appears here. In addition, I believe the reason transferring the oligomers to pH 7 strengthens
this signal is because the oligomers precipitate (as shown in Figure 3.5 and more heavily
concentrate on our crystal.
3.6.2 ThT Fluorescence
As previously discussed, fluorescent dyes are commonly used to detect amyloid
aggregates, most commonly with Thioflavin-T However, there are some oligomer species that
show little to no ThT fluorescence (63). Even if responsive to ThT, I wanted to determine their
ThT fluorescence relative to the gO/CFs formed above the COC. ThT fluorescence was
determined from 100 M solutions of all three amyloid species at pH 2. In addition, the cut-off
filters during TO isolation was used as hydrolyzed monomer sample. Figure 3.7 shows the ThT
(15 M) fluorescence excitation and emission spectra in the presence of RFs, TOs, CFs,
hydrolyzed and native monomers. Hydrolyzed monomers induce a weak (not resolved in Fig.
3.7) two-fold enhancement in ThT fluorescence over native monomers. TOs result in a 14-fold,
CFs in a 24-fold and RFs in a nearly 150-fold enhancement of ThT fluorescence. The ThT
enhancement induced by the toxic oligomers further supports the idea that these toxic
aggregates are indeed amyloid oligomers. Comparing ThT fluorescence from isolated toxic
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oligomers to that of hydrolyzed monomers also indicates that the ThT fluorescence of the tOs is
distinct from hydrolysis-induced changes in ThT responses to monomers.

Figure 3.7: ThT Spectra of isolated aggregates
ThT excitation and emission spectra for RFs, TOs, CFs, as well as native and hydrolyzed monomers. All
spectra were collected using 100 µM of protein and 15 µM ThT. TOs show Thioflavin-T fluorescence and
notably at a comparable level to that of CFs.

3.6.3 Immunostaining with the oligomer sensitive antibody A11
A common assay for detection of oligomers is immunostaining with oligomer-selective
antibodies (44,45). These antibodies are formed by immunizing animals with amyloid oligomers
and extracting their immune serum. It has been shown that these antibodies formed against
amyloid oligomers of one protein can be used to detect amyloid oligomers from different
proteins. However, there are some contradictory reports as to whether A11 binds to HEWL
oligomers (29, 30). We used dot-blots with two different variants of A11 to determine their
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response to the three HEWL amyloid aggregate species RFs, CFs and TOs. Preliminary
experiments by my fellow graduate student Nabila Bushra indicated that RFs did bind to the
nitrocellulose membranes used for dot blots. Ms. Bushra used Ponceau staining to determine
the differences in deposition and retention rates of RFs relative to all the other amyloid
aggregates. These experiments indicated that RF concentrations had to be reduced by a factor
of 4 relative to the other amyloid aggregates in order to retain equivalent amounts of protein
on the membrane prior to antibody application (Figure 3.8 Left). The difficulty of getting
oligomeric HEWLaggregates to adhere to the membranes might explain some of the
discrepancies in the immunostaining from earlier work.
Dot blots with either A-11 (Novus Biologicus) or A11-19 (gift from Rakez Kayed)
antibodies were performed with concentrations adjusted to result in comparable amounts of
total protein for each aggregate type. Figure 3.8 (Middle) shows the Novus A-11 antibody
reacting to both RFs and CFs. While A11-19 also reacted to RFs, it reacted with TOs instead of
CFs. This suggests that both variants of A11 do have a rather prominent affinity to hewL RFs. At
the same time, the select reactivity of A11 and A11-19 to the two different HEWL oligomer
species serves as further evidence that the underlying conformations of these two oligomer
species are distinct. Unfortunately, the cross-reactivity of both A11 variants with RFs means
immunostaining is not a feasible method of oligomer detection for this system. Additionally,
many attempts to replicate these results have been made and Ms. Bushra has found the
immunostaining of Novus A11 body to be highly reproducible, reactivity towards RFs and TOs,
but some has found some variability with A11-19 immunostaining where reactivity towards
both oligomer types may occur.
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Figure 3.8: A11 antibody immunostaining
Immunostaining of amyloid aggregates with A11 and A11-19 anti-oligomer antibody. (Left) Ponceau
staining of aggregates blotted onto membrane. (Middle) Reactivity of A11 from Novus Biologicus with
RFs (top row) and late-stage oligomers (middle row) (Right) Reactivity of A11-19 with RFs (top row),
toxic oligomers (2nd row) and native monomers (bottom row). The concentrations used for the various
aggregate were RFs: 2, 1 and 0.5 mg; toxic oligomers: 4, 2 and 1 mg; and for every other sample 12, 8
and 4 mg. These concentrations were used as they were found to yield equal protein deposition on the
membrane for each aggregate species

3.7 Origin of Toxic Oligomer and Time-course of their Formation
3.7.1 Are Toxic Oligomers Fibril Derived?
As shown in Figure3.9, tOs do induce ThT fluorescence comparable in intensity to that
generated by early-stage gO/CFs. Yet, our kinetic measurements of fibril growth below the COC
lacked any sign of TO formation during the lag-phase of RF growth. In addition, we were only
able to isolate TOs at the late-stages of fibril formation. One possible explanation was that tOs
were actually directly derived from rigid fibrils, perhaps by dissociating off of RFs, or RFs being
necessary to catalyze TO formation.

45

Figure 3.9: Seeded Rigid fibril growth
Above (left) shows ThT growth kinetics of fresh monomers, isolated fibrils and monomers seeded with
rigid fibrils, incubated at 52C. Seeded rigid fibril sample shows immediate RF formation with no lag
phase (templated growth). Right shows the FPLC traces of the seeded sample after 2 days along with UV
traces of native monomers and typical RF Sn to compare. No oligomeric peak was found from seeded
grown rigid fibrils.

As a result, the dominant light scattering and ThT fluorescence from fibril formation
would mask any minor contributions from concurrent tO formation. This would also agree with
the observations of "oligomeric clouds" surrounding dense core plaques in Alzheimer’s disease
(59). I therefore investigated two possible mechanisms by which fibrils could generate toxic
oligomers. Firstly, rigid fibrils could be the immediate source of toxic oligomers by shedding
them over time. Secondly, fibrils might act as catalysts promoting the formation of toxic
oligomers from monomers.
If isolated fibrils "shed" toxic oligomers they should do so in the absence of any
monomers and, therefore, in the absence of fibril growth. To test this, isolated RFs were
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generated using our typical centrifugation protocol. The 4 th fibril pellet was resuspended in pH
2 buffer at 25 C. After several days of incubation, RFs were removed from solution by
centrifugation at 15,000 g overnight, and the protein concentration of the supernatant was
determined. This did result in an elevated protein concentration in the supernatant. However,
further inspection revealed that centrifugation had “fragmented” some fibrils which, therefore,
had remained in the supernatant after one centrifugation cycle. After filtering out these
fragmented fibrils with a 50 nm syringe filter, the protein concentration in the supernatant was
at a level indistinguishable from that prior to the incubation of the isolated fibrils. Incubation of
isolated fibrils at the growth temperature used for fibril growth yielded comparable negative
results.
Alternatively, I checked whether rigid fibrils "catalyzed" the formation of toxic oligomers
from monomers. If so, seeding of monomers with preformed rigid fibrils should accelerate the
formation of toxic oligomers. To test this idea, we incubated three different solutions
containing either monomers only, isolated RFs only, or monomers seeded with isolated RFs in
the presence of 15 M ThT, and measured ThT fluorescence over time. Incubating the seeded
sample at the usual growth temperature of 52 C induced immediate RF growth, as indicated by
a rapid increase in ThT fluorescence. Both the monomer and fibril controls showed no increase
in fluorescence and remained unchanged for 24 hours. Hence neither of the two control
conditions (monomers only, fibrils only) generate toxic oligomers with in this time frame.
Therefore, any toxic oligomers detected in the seeded solution would have to be the result of
fibril-catalyzed oligomer formation.
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The observed increase in ThT fluorescence of the seeded sample in Figure 3.9, by itself,
does not provide any information about possible toxic oligomer formation since it is dominated
by rigid fibril elongation. To check for toxic oligomer formation, the sample was spun overnight
at 15,000 gs and the supernatant collected. This supernatant was then passed through the size
exclusion column in FPLC to check for the presence of oligomers. The UV trace in Figure 3.9
indicates that no toxic oligomers appeared as a result of seeded fibril growth, as only the single
monomer peak is present in this trace.
3.7.2 Time-course of Toxic Oligomer Formation
These experiments indicated that toxic oligomers were neither shedding from rigid
fibrils, nor did they form as a result of fibril-mediated catalysis from monomers. This implied
that toxic oligomers formed along a pathway distinct from fibril formation, possibly even
competing with the latter for monomers.
The first step in exploring this hypothesis was to determine when exactly during RF
formation toxic oligomers did form. In contrast to the globular oligomers that form above the
COC, neither DLS nor ThT fluorescence indicated oligomer formation below the COC during the
lag phase of rigid fibril formation. Since tOs do have ThT responses similar to those of the gO/CF
formed above the COC (see section 3.6.2. above), it implied that toxic oligomers were late-stage
aggregates formed during or after fibril nucleation and growth. However, this prevented us
from detecting toxic oligomers using DLS or ThT as both of these signals were dominated by RF
formation at that point.
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In order to measure the onset of toxic oligomer formation a series of solutions identical
to those used for generating TOs during RF growth: 20 mg/ml of HEWL, 50 mM NaCl, adjusted
to pH 2 were incubated at 52 C. I stopped their incubation at different time points and using
physical separation from both fibrils and monomers was able to determine their tO content at
these respective time points. The series of solutions was incubated both in 15 mL test tubes,
with 3 mL of solution, and in 96 well plates, with 250 L of solution each. Firstly, incubating
samples in a 96 well plate allowed me to monitor RF formation by measuring ThT (15 µM)
fluorescence. Additionally, we had noticed that the smaller volume of the well plates
accelerated RF formation compared to the larger volume incubated in my 15 mL test tubes.
This is most likely due to the preferential nucleation of RFs at the air/water interface, combined
with the larger surface to volume ratio of the smaller wells versus our other containers used for
incubation such as test tubes. These two separate incubation conditions thus alter the time
scale for RF formation, while still keeping solution conditions constant. Hence, following tO
formation under these two different conditions allowed me to determine whether the time
course of RF and tO formation are correlated or not.
Toxic oligomer concertation under both growth conditions (96 well plate and test tubes)
was determined by isolating toxic oligomers at various time points, roughly every 24 hours, via
centrifugal cut-off filters (this protocol was described in Section 3.5). Solutions from several
wells of the 96 well plates were pooled in order to use identical solution volumes for the
subsequent tO isolation and measurement. Toxic oligomer concentration measurements were
then taken using DeNovix UV spectrometer
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Figure 3.10: Time course of TO formation
HEWL was incubated in 15 ml tubes (orange) or in 96 well plates (blue) at 20 mg/ml hewL, pH 2, 50 mM
NaCl (below COC conditions). Toxic oligomers were physically separated and their concertation was
measured with UV absorption daily. ThT fluorescence was monitored continuously for the solutions
incubated in the plate reader. Toxic oligomers were found to have a delay before formation, and
additionally accelerating rigid fibril formation (via smaller incubation volume in 96-well plate) delayed
toxic oligomer formation.

The concentration of toxic oligomers, measured with UV absorption, along with the ThT
fluorescence of the samples in the plate reader is plotted versus time in Figure 3.10. Measured
toxic oligomer concentrations clearly show an extended lag period before the onset of toxic
oligomer formation. The 3 mL solutions indicate rapidly forming toxic oligomers after a 4 day
lag period. This closely matches the lag periods for RF formation under these growth
conditions. In contrast, the plate reader samples only showed toxic oligomer formation after 6
days while the RF lag period is shortened to two days. Hence, accelerating fibril formation
deaccelerated toxic oligomer formation. This implies not only that toxic oligomers are off-
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pathway to rigid fibril growth but, at a minimum, are competing with each other for the same
pool of monomers for their respective growth.
3.7.3 Monomeric Composition of Toxic Oligomers
One possible explanation for the delayed onset of toxic oligomer formation could be
that they require at least partial hydrolysis of HEWL monomers which is progressing quite
slowly under the pH and temperature conditions (pH 2 and 52°C) used for RF growth (51). This
does, in turn, imply two distinct scenarios for TO formation. For one, TOs could form
preferentially form from a fully hydrolyzed fragment of HEWL monomers. Alternatively, TO
formation from HEWL monomers requires the additional flexibility that comes from partial
hydrolysis of the monomers, In this case, partially hydrolyzed but still full-length monomers
(with their disulfide bonds holding them together) should form the building block for TOs.
In collaboration with my lab mate Palle K. W. Karunarathne, we tested the role HEWL
hydrolysis in toxic oligomer formation, and determined whether they are formed from fulllength but partially hydrolyzed monomers or from a hydrolyzed fragment. Towards that end,
we ran reducing SDS-PAGE gels using native monomers as well as toxic oligomers and their
corresponding monomer fraction, to compare monomeric composition between these samples.
Using a reducing gel assures that we observe the full extent of hydrolysis of the sample. If
some fully hydrolyzed fragments of HEWL were the main source of toxic oligomers, though, one
would expect to see an accumulation of this hydrolyzed fragment in the toxic oligomers,
relative to the composition of the hydrolyzed monomers present in solution at that time. Figure
3.11 shows that both hydrolyzed monomer and the toxic oligomer samples contain identical
amounts of all hydrolyzed fragments. Hence, they are composed of the same partially
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hydrolyzed monomers present in solution instead of selectively accumulating a particular HEWL
fragment. This also supports that it is the aforementioned increased monomer flexibility from
being partially hydrolyzed that is required for toxic oligomer formation, and not instead the
need of some specific hydrolyzed HEWL fragment. .

Figure 3.11: SDS-Page gel of TOs and Hydrolyzed Monomers
Reducing SDS PAGE gel of native monomers, hydrolyzed monomers and toxic oligomers. The gel indicate
a noticeable amount of partial hydrolysis of the incubated HEWL monomers and toxic oligomers.
Importantly, there is no discernable difference in the composition of hydrolyzed material between the
hydrolyzed monomer and toxic oligomer sample. Specifically, no enhanced hydrolyzed fragment within
TOs showing they are composed from partially hydrolyzed material and not from any specific hydrolyzed
fragment.
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3.8 Discussion
The specific role amyloid oligomers play in the pathogenesis of various amyloid
diseases remains an area of active research (67). Recent findings have indicated that amyloid
oligomers themselves display polymorphism when generated in vitro (65-67), as well as when
isolated from patient post mortem (67-69). Furthermore, it was implicated that these different
oligomer "strains" are associated with different disease pathologies (69-71). However, it has
remained less clear what the mechanisms are that result in the formation of distinct oligomer
species. In addition, most of the isolation and characterization of these distinct oligomer
strains has relied on either immunohistochemistry or on some level of cell/tissue toxicity
evaluation as means for their identification and characterization. Overall, my thesis research
was to gain new insights into the mechanisms underlying the formation of distinct oligomer
species, to provide a more detailed biophysical characterization of amyloid oligomer species
and their interactions with amyloid fibrils, and to identify straight-forward fluorescence assays
for the select detection of amyloid oligomers in vitro and, potentially, in vivo.
I have shown that HEWL can form two distinct types of amyloid oligomers. The first
oligomer type, gOs, begin forming immediately upon incubation, but only under condition
above a threshold concentration we called the critical oligomer concentration, or COC. The
second, new type of oligomers, TOs, forms under conditions associated with gO-free fibril
growth. It emerges on a time scale that typically overlaps with fibril formation in lysozyme and,
therefore, was obscured in kinetic traces and high resolution images by the latter. I
characterized this second type of oligomers and found several similarities but also several
differences between them and their early-stage gO counterpart.
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The most notably and relevant difference between these two oligomer populations is
the dramatic difference in the level of cell toxicity induced by the toxic, fibril-associated
oligomers compared to the early-stage oligomers. This is the reason I refer to the former as
toxic oligomers (TOs). Another difference is the type of precipitates formed upon transfer to pH
7. GOs formed precipitates whose morphologies closely resembled that of diffusive plaques.
Diffusive plaques are found in early stage AD patients but are shown to be relatively inert since
they are also found in cognitively normal people. This finding, of negligible toxicity and
resemblance to diffusive plaques, in gOs, is at variance with the hypothesis that oligomers are
always the most disease relevant aggregate population. In addition, we have shown that gOs
are off-pathway from fibril formation but strongly affect fibril growth. First of all, they compete
with fibrils for the same monomer pool for growth, thereby retarding the late-stages of fibril
elongation. In addition, I helped establish that gOs directly interact with rigid fibrils and
thereby inhibit secondary fibril nucleation. Therefore, gOs might actually help retard the
progression of amyloid diseases in vitro. These are, however, only hypotheses. For example, our
German collaborator, Dr. Wolfgang Hoyer, showed that Aβ1-40 gOs generated in their lab, have
minimal cell toxicity but did interfere significantly with synaptic transmission in neuronal cell
cultures (72). In addition, the discovery of another type of highly toxic oligomers demonstrates
that there are likely multiple distinct oligomer polymorphs with distinct biological activity. It is
therefore important to develop an understanding of how these different oligomer polymorphs
come about, how to readily identify them and how to relate their underlying structural
characteristics to the corresponding difference in biological activity.
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At first, the origin and mode of growth of this new species of toxic oligomers remained
enigmatic. Prior to our cell toxicity experiments, neither our studies on the kinetics of amyloid
formation in HEWL nor high-resolution imaging with TEM or AFM had turned up any evidence
for their existence under sigmoidal fibril growth conditions. Therefore, one main focus of my
thesis work was to elucidate the origin of this new oligomer species, determine its mode of
formation, and to provide some biophysical and immunological characterization of its
properties. After developing our assay for isolating tOs from fibrils and monomers, I
established that tOs, under our growth conditions, start forming after the onset of rigid fibril
nucleation and growth. This is in stark contrast to gOs, which immediately grow upon
incubation and dominate during the lag phase of rigid fibrils formation. Since DLS and ThT
signals are both decidedly biased in favor of RFs, the emergence of tOs during RF growth
explained why we had previously missed the former in our kinetic studies of amyloid growth. It
also implies that kinetic and imaging studies can readily miss admixtures of oligomers in fibril
samples due to their select sensitivity to fibrils.
There are two previous studies that reported toxic oligomers forming after extended
incubation under rigid fibril growth conditions of lysozyme (57,58). However, their growth
conditions are somewhat distinct from ours and both studies lack a detailed characterization of
oligomer morphologies which makes a clear assignment of what type of oligomer they
observed difficult. The measured time-course of HEWL toxic oligomer formation provides
evidence that these oligomers grow along a pathway competing with rigid fibrils, and are not
on-pathway pre-cursors of fibrils. This is in contrast with a study of IAPP, which showed toxic
oligomers forming in the lag phase of rigid fibril growth (63). In contrast to HEWL gOs, the IAPP
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oligomers were also ThT negative. This suggests that both the type of amyloid protein and the
specific growth conditions they are forming under play a role in the type of amyloid oligomers
they form and the level of cell toxicity they display.
Based on our findings I theorized that the delayed onset of tO growth may be due a
gradual increase in hydrolyzed HEWL. Since monomers could form gOs during the lag phase, i.e.
when monomer hydrolysis was still minimal, this further suggested that it was the increase in
structural flexibility with progressive hydrolysis that could play a role in the formation of
different oligomer species. This also matched the prior observation on point mutations of
Human Lysozyme associated with Lysozyme amyloidosis. These mutants were all structurally
nearly indistinguishable from the native form but displayed lower thermal stability and higher
overall flexibility (46, 81, 82).
When investigating the characteristic of both types of oligomers several similarities and
important distinction between the two emerged. FTIR of both oligomers displayed a beta sheet
peak around 1618 cm-1 which is indicative of their underlying amyloid-like structure. Notably,
the beta sheet peak for both oligomers is shifted marginally but reproducibly from that for rigid
fibrils, which is located at 1624 cm-1 (Figure 2 in Chapter 2). However, our preliminary data also
indicate that there is an additional peak located in the 1700-1680 cm-1 range. This peak is
typically associated with anti-parallel beta sheet content and is measurably larger for TOs than
gOs. This anti-parallel beta sheet is a structural distinction between oligomers and amyloid
fibrils observed in multiple systems, including Aβ (47, 73, 74). The extent of this anti-parallel
beta sheet content might provide a structural basis for the degree of amyloid oligomer toxicity,
and why it is distinct from that of amyloid fibrils. This hypothesis correlates well with the
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distinct toxicity of these two oligomer species, where the oligomers with the most anti-parallel
structure, TOs, are also by far the most toxic.
Overall, generating two distinct types of oligomers, with different levels of toxicity, is an
important step towards understanding the mechanisms regulating oligomer formation in
disease. In particular, the cellular compartments in which oligomers form not only affect
oligomer formation by the inherent changes in the solution environment but might affect the
type of oligomer species that emerge by modulating the structural flexibility of the monomers.
Identifying the distinctions of different type of amyloid oligomer species, and how those
distinction translate to their relative toxicity, emphasizes the importance of an efficient
approach to oligomer detection in amyloid research. A simple adaption to my previously
described dye screening assay (Chapter 2), allows us to extend our dye screen to selective
fluorescence dyes for HEWL TOs. As previously shown, pH 2 HEWL oligomers of either type, and
fibrils precipitate when transferred to pH 7, with gO and RF precipitates resembling either
diffusive or neuritic plaques, respectively (Figure 3.1). This suggests a modification to my
original dye screening assay that takes advantage of this precipitation to look for oligomerselective dyes, and to do so under more physiological solution conditions. Isolated amyloid
aggregate samples could be transferred to pH 7 with dyes added to these precipitates at that
point. Any oligomer-selective dye discovered under these conditions is automatically more
likely to work under in vivo conditions. Figure 3.12 show a bar graph of preliminary
measurements using this approach with ThT (10 uM) and CV (5 uM) fluorescence from HEWL
aggregates. While some troubleshooting is required to transition the dye assay to this new
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protocol, the results look reasonable with CV fluorescence from all amyloid aggregates
comparable, while ThT fluorescence remains highly selective for RFs.

Figure 3.12: ThT and Cv fluorescence of pH 7 transferred amyloid aggregates
Above shows a bar graph of florescence of RFs, CFs, TOs, and Monos plotted as a normalized fold
enhancement from buffer. Fluorescence was measured in a 96-well plate reader with pH 7 transfer
accomplished by diluting pH 2 amyloid aggregates at a 10-fold dilution with pH 7 25 mM Sodium
Bicarbonate buffer.

3.9 Materials and Methods
3.9.1 Aggregate Sample preparation
Lyophilized hen egg white lysozyme (HEWL) was purchased from Worthington Biochemicals. All
aggregate species of HEWL, rigid fibrils (RFs), toxic oligomers (TOs) and globular oligomers/curvilinear
fibrils (gOs/CFs), were grown at pH 2. The pH of DI water was adjusted to pH 2 by adding small amounts
of HCL to aqueous solutions of both 50 mM and 250 mM NaCl. HEWL was dissolved in this solution to
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prepare 20 mg/ml in the pH 2 50 mM NaCl solution (for formation of RFs and TOs) and 250 mM NaCl (for
formation of gO/CFs). Samples were filtered through 220 nm PVDF (Fisherbrand, Fisher Scientific) and
incubated at 52C in a heat block. RF and TO samples were incubated for 7-9 days and gO/CF samples
were incubated for 2-4hrs and monitored with dynamic light-scattering (DLS).
3.9.2 Isolating of amyloid aggregates
Distinct aggregate species were isolated from monomers via centrifugation. After incubation 2
mL of both RF (50 mM NaCl) and gO/CF (250 mM NaCl) samples were spun for 22-24 hours at 15,000g.
The RF supernatant and both RF and CF pellets were collected. Aggregate pellets were re-suspended in
1.6 mL their respective solutions and spun again for 22-24 hour. This processes was repeated 3 times or
until monomer concentration measured in supernatant was less than 1% of aggregate concentration in
the pellet. The toxic oligomers present in the RF supernatant, were isolated from HEWL monomers via
50 kDa molecular weight centrifugal cut-off filters (Millipore Sigma Amicon, Fisher Scientific). Cut-off
filters, with 500 uL RF SN, were spun at 15,000 gs for 15 min and filtrate was often collected to act as
hydrolyzed monomer control in many experiments. Typically, sample was washed by adding 200 uL of
50 mM NaCl pH 2 solution to top of filter and spinning cut-off filter at 15,000gs for 15 min. After three
washes filter was flipped and put in new centrifuge tube and spun at 1000g for 5 minutes to collect
isolated toxic oligomers.
3.9.3 Cell Toxicity Experiment

Human lung carcinoma cells (A549) were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% (v/v) fetal bovine serum and 2 g/L NaHCO 3 . Cells were kept in a 5% CO2
humidified atmosphere at 37°C. Cells were then plated with 10,000 cells/well in 96-well plates and
incubated for 24 hours. Then the medium was exchanged with Dulbecco’s modified Eagle’s medium
without fetal bovine serum. The plate was incubated for 20 more hours. After this amyloid
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aggregates were added to the cell. Isolated aggregates were diluted in cell media to desired
concentrations before adding to the cells. Once added cell plates were incubated for 72 hours.

Before beginning fluorescence imaging cells were washed with PBS twice. 4 µM of Ethidium
homodimer-1 (Life Technologies (catalogue number E1169)) was added to each well. Plate was
than incubated another hour before exchanging the cell media with media containing NucBlue
(Life Technologies (catalogue number R37605)) (2 drops of dye to 1 ml of cell media). Five or 6
images were then taken per well using the EVOS fluorescence microscope (10X magnification),
and live cells were counted using ImageJ software.
3.9.4 Dynamic Light Scattering
A Zetasizer Nano S (Malvern Instruments, Worchestershire, UK) with a 4 mW He-Ne
laser (λ = 633 nm) in back scattering geometry (θ = 173◦) was used to perform dynamic light
scattering (DLS) measurements. Correlation functions were collected over three minutes, and
were converted in particle size distributions via the built in deconvolution analysis package in
the Zetasizer software.
3.9.5 Fast protein liquid chromatography
A Superdex 75 10/300 GL column (GE Healthcare) was connected to an ATKA-pure
purification protein system pump (GE Healthcare) and was washed for 2 column lengths with
water, and then washed with the same buffer as the sample is in. Both of these wash steps
were done with column down flow and a flow rate of 0.5 mL/min. Sample were typically
injected at 1-2 mg/mL with a sample volume of 300-500 µL into the system. Column pressure
was monitored for any fluctuations corresponding to bubbles within the system. UV absorption
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was also measured and any observed peaks were fractionated and collected into test tubes.
The column was then cleaned by running two column volumes of water upward through
column followed by 1 -2 column volumes of ethanol, both steps again at 0.5 mL/min. Column
was kept in FPLC unit while filled with ethanol until next uses.
3.9.6 Fourier Transform Infrared Spectroscopy Measurements
Fourier Transform infrared Spectroscopy (FTIR) measurements were taken on a Bruker
Optik Vertex 70 (Ettlingen, Germany) spectrometer. Typically, 27 µL of solution were added to
the top of silicon crystal used for the ATR setup of this instrument. Background scans of the
solvent solution were taken over 1200 scans at 2 cm-1 resolution. Sample spectra would be
measured from 3000 to 1000 cm-1 wavenumbers, with 600-1000 scans taken depending on the
intensity of the signal compared to background. FTIR spectra in the Amide I Band between 1600
to 1700 cm-1 were normalized to either their peak values or their total area under the peak.
Difference spectra for aggregate samples were created by subtracting the normalized monomer
IR spectrum from the normalized spectrum of the amyloid aggregate sample.
3.9.7 Thioflavin-T Excitation and Emission Spectra
A FluoroMax-4 spectrofluorometer (Horiba) was used for all fluorescence
measurements.15 µM of ThT was added to the sample and was typically excited at 445 nm and
emitted at 480 nm. Spectra were measured at room temperature with an average of 5
accumulations taken for each spectra measurement.
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3.9.8 Immunostaining
2 µL of sample were spotted on nitrocellulose membranes (Thermo fisher pierce).
Membranes were blocked with 7% milk in 1X TBS at room temperature for 1h. Membranes
were washed three time by swapping TBS buffer after five minutes each wash. Then
membranes were incubated for 18 hours at 40C with 1:1000 dilution of primary antibody, A11
(Novus biological) A11-19 antibody (gift from Dr. Rakez Kayed). Membrane were then washed
again and were incubated in 1:1000 dilution of Ig goat anti-rabbit antibody (Southern biotech)
for 1 h at room temperature. After 1 h, membranes were again washed and ECL western
blotting substrate (Thermo fisher pierce) were added. Membranes were imaged using the
Chemidoc imager (Bio-Rad).
3.9.9 Fluorescence measurements of growth kinetic
Fluorescent kinetic measurements were performed using one of two plate readers: a
SpectraMax M5 grating based fluorescence plate reader (Molecular Devices, San Jose, CA) or d
a Fluorostar Omega plate reader (BMG Labtech, Cary, NC). Typically, 270 µL of sample were
added to a well in 96-well glass bottom plates (Cellvis, Mountain View, CA) and monitored at
growth temperatures. Typically, fluorescent readings were acquired every 15-20 minutes for
several days.
3.9.10 Reducing SDS-Page Gel
Isolated amyloid aggregate samples were prepared. All samples were analyzed using 10–
20% gradient Tris-tricine gels (Criterion, Bio-Rad) and a sodium dodecyl sulfate (SDS) running
buffer without glycine. 2 mg/ml of sample were mixed with Tricine sample buffer (Bio-Rad) in the
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presence of 2% (v/v) 2-Mercaptoethanol (Fisher Scientific) in 1:1 ratio and heated for 5 minutes
at 90 °C. 30 µL of each sample was loaded onto precast gels (Criterion 10%-20% Tris-Tricine) and
run for about 1.5 hours at 105 V. The gel was fixed in a solution of 40% methanol and 10% acetic
acid for 30 minutes, stained for 2 hours using Coomassie blue (G-250 stain, Bio-Rad) for 1 hour,
and was washed overnight with DI water.
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Chapter 4 - Summary
In Chapter 2, I describe the formation of HEWL oligomers above a concertation
threshold, referred to as the “critical oligomer concentration”. This onset of oligomer formation
led to a transition from sigmodal growth kinetics to biphasic. Using these two pathways of
aggregation I developed an assay to screen fluorescent dyes for potential selectivity toward
oligomers.
Fluorescent dyes are an excellent method of detection for oligomers ex vivo and with
possibilities of development for in vivo detection. Some dyes have been reported to be
oligomer selective, but in many cases the results were inconclusive, or the dyes required
custom synthesis and thus were not readily commercially available (75-77). Using the above
kinetic approach, I found a good candidate for an oligomer selective dye in Crystal Violet (CV).
Crystal Violet is commonly used in bacterial staining and is readily available. Crystal Violet has
similar fluorescence responses to oligomers as the “industry standard” amyloid dye ThioflavinT, but is significantly less fluorescent when bound to rigid fibrils. This suggests that dual ThT and
CV staining would provide complimentary information to help differentiate between rigid fibrils
and oligomers. As an example, in ex-vivo staining one could use the membrane permeant
variant of ThT, Thioflavin-s (ThS) and CV to stain amyloid plaques in brain tissue. Sections with
strong ThT fluorescence but marginal CV fluorescence would likely be mostly composed of rigid
fibrils, while sections where the two dyes fluorescence are comparable would likely be
composed of oligomers.
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Furthermore, I showed that amyloid beta peptide undergoes both sigmodal and
biphasic growth conditions when crossing a concentration threshold in the same manner as
HEWL. This implies that the same dye screening assay I performed with HEWL in chapter 2,
could instead be extended to amyloid beta and be performed under physiological solution
conditions. This is crucial as dye fluorescence is known to have significant solution condition
dependence. Fluorescent dyes that appear oligomer selective under this amyloid beta dye
screening assay would be excellent candidates for oligomer selective dyes in vivo.
Finding methods for oligomer detection, as described in chapter 2, remains linked to the
question whether that specific oligomer species is the most disease-relevant polymorph. In
chapter 3, I referred to a previously performed cell toxicity experiment by Chamani Niyangoda.
She compared the toxicity of HEWL rigid fibrils to the oligomers formed above the COC. In this
assay she found a surprising level of toxicity in one of her controls, the rigid fibril supernatant.
Based on this toxicity result I confirmed the presence and characterized another distinct type of
oligomers forming from HEWL than the previously described oligomers emerging above the
COC.
This new polymorph of oligomers differed from those studied in chapter 2 by its level of
cytotoxicity but also in its immunostaining response with the oligomer selective antibody A11.
Another difference between these oligomers is the type of precipitates formed upon transfer to
pH 7. GOs formed precipitates with morphologies that resembled diffusive plaques. Diffusive
plaques are found in AD patients but are considered to be relatively innocuous. This is at odds
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with the hypothesis that oligomers are always the most disease relevant aggregate population.
But the second type of oligomers I characterized had high levels of cell toxicity
I found this new type of oligomer to be likely composed of dimers and trimers. Previous
studies have implicated amyloid beta dimers as the building blocks for toxic aggregates in AD
(78-80) and have drawn an inverse correlation between size and an oligomers deleterious
effect (67). The size of the species of HEWL oligomers I identified therefore lines up with this
hypothesis. The underlying size differences of the two HEWL oligomer species may be a
possible reason for the different levels of their cytotoxicity.
In contrast to the oligomers described in chapter 2, this new type of oligomer formed
below the COC. I therefore investigated the possible origins of these oligomers. Initially I
believed the oligomers were somehow fibril derived, perhaps dissociating off of the fibrils.
Several experiments described in Chapter 3 provide evidence that this is not the case. Instead I
suggest these oligomers form as monomers reaching a threshold in flexibility. In this system this
flexibility threshold is reached due to the progressive hydrolysis of HEWL under our growth
conditions. This hypothesis emerged as the measured time delay before oligomer formation
matched with the slow progression of HEWL hydrolysis. Additionally, the idea of flexibility as an
underlying threshold for amyloid formation is not a new idea for lysozyme amyloidosis. The
propensity for human Lysozyme mutants’ propensity to aggregate to the increased levels of
flexibility present in disease-relevant point mutants versus their native counterpart (46, 81, 82).
Identifying different mechanisms resulting in the formation of distinct oligomer polymorphs is
an important step towards understanding the role of oligomers in amyloid assembly and
disease.
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While other studies showing different types of oligomers have been performed
previously (65-70), these often only characterized their aggregates via cell toxicity or in some
cases immunostaining. To my knowledge, few studies have characterized these oligomers
biophysically or explored the underlying mechanism behind distinct oligomer formation as I’ve
done in Chapter 3. Overall, generating different oligomer species, with varied cell toxicity, is an
important step towards understanding the mechanisms regulating oligomer formation in the
body. Specifically, the solution conditions in cellular compartments not only affect oligomer
formation but might affect the type of oligomer species that emerge by modulating the
structural flexibility of the monomers. These findings further emphasize how proper
characterization, and consequentially proper detection, of oligomer types is necessary if we are
to understand the role oligomers play in amyloid disease.
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